Table 3

Progression-free survival (PFS) and overall survival (OS) between patients with pathogenic or likely pathogenic (P/LP) alterations compared with those with VUS

P/LP* n=46VUS n=55
PFS
 Median PFS, months (95% CI)8.4 (5.2 to 23)3.4 (2.8 to 4.3)
 6-month PFS (95% CI)†0.59 (0.47 to 0.73)0.27 (0.17 to 0.45)
 12-month PFS (95% CI)†0.46 (0.34 to 0.61)0.10 (0.04 to 0.27)
 HR (95% CI)0.42 (0.26 to 0.68), p=0.0003Reference (1.0)
OS
 Median OS, months15.5 (10.3 to 25.1)9.5 (7.6 to 21.3)
 6-month OS (95% CI)†0.71 (0.60 to 0.84)0.73 (0.6 to 0.87)
 12-month OS (95% CI)†0.58 (0.46 to 0.73)0.39 (0.26 to 0.57)
 HR (95% CI)0.62 (0.39 to 1.01), p=0.053Reference (1.0)
  • *P/LP show similar proportions and are combined.

  • †Proportion.

  • VUS, variants of unknown significance.